Other novel immunosuppressants.
The use of immunosuppressive agents in dermatology has increased widely. The role of these medications has become increasingly important for the treatment of dermatologic disorders in an inpatient setting, where there is frequently a requirement for highly potent, fast-acting, effective agents. This article presents an overview of the general application, mechanisms of action, metabolism, and adverse effects commonly associated with systemic immunosuppressive agents used in dermatology.
Flores
F
F
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Florida, USA.
Kerdel
F A
FA
D001379:Azathioprine / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy*; D016559:Tacrolimus / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D002699:Chlorambucil; D016572:Cyclosporine; D013866:Thioguanine; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate